Medicamen Biotech shareholders and shareholding pattern
NSE: MEDICAMEQBSE: 531146Pharmaceuticals & BiotechnologySmall Cap
Last close ₹253.35down ₹11.80 (4.45%)BSE ₹253.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹265.15.
52-week range of traded prices to 23 Oct 2026
₹212.40Low, 29 Jun 2026₹447.65High, 25 Nov 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹344 Cr1,991st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.39%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 3.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day.
- 20,122
Who owns Medicamen Biotech, filing by filing
Per cent of the company's shares. The last ten years of filings, from Dec 2016; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters40.46%
- Foreign institutions4.49%
- Indian institutionsNone
- Governments0.05%
- Individuals and others55.00%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Governments
- Individuals and others
| Per cent | Dec 2016Filed 17 Jan | Mar 2017Filed 11 Apr | Jun 2017Filed 7 Jul | Sep 2017Filed 13 Oct | Dec 2017Filed 20 Jan | Mar 2018Filed 18 Apr | Jun 2018Filed 10 Jul | Sep 2018Filed 27 Oct | Dec 2018Filed 20 Jan | Mar 2019Filed 16 Apr | Jun 2019Filed 19 Jul | Sep 2019Filed 9 Oct | Dec 2019Filed 10 Jan | Mar 2020Filed 15 May | Jun 2020Filed 17 Jul | Sep 2020Filed 12 Oct | Dec 2020Filed 18 Jan | Mar 2021Filed 7 Apr | Jun 2021Filed 19 Jul | Sep 2021Filed 20 Oct | Dec 2021Filed 17 Jan | Mar 2022Filed 18 Apr | Jun 2022Filed 15 Jul | Sep 2022Filed 20 Oct | Dec 2022Filed 16 Jan | Mar 2023Filed 19 Apr | Jun 2023Filed 20 Jul | Sep 2023Filed 19 Oct | Dec 2023Filed 12 Jan | Mar 2024Filed 17 Apr | Jun 2024Filed 18 Jul | Sep 2024Filed 8 Oct | Dec 2024Filed 21 Jan | Mar 2025Filed 19 Apr | Jun 2025Filed 24 Jul | Sep 2025Filed 17 Oct | Dec 2025Filed 16 Jan | Mar 2026Filed 16 Apr | Jun 2026Filed 16 Jul | Sep 2026Filed 22 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.51% | 45.51% | 46.87% | 46.87% | 46.66% | 45.37% | 46.02% | 46.02% | 44.53% | 44.53% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.83% | 44.83% | 44.83% | 43.60% | 43.60% | 43.60% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 42.99% | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | |
| Indian promoters | 45.51% | 45.51% | 46.87% | 46.87% | 46.66% | 45.37% | 46.02% | 46.02% | 44.53% | 44.53% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.77% | 44.83% | 44.83% | 44.83% | 43.60% | 43.60% | 43.60% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 43.21% | 42.99% | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 54.49% | 54.49% | 53.13% | 53.13% | 53.34% | 54.63% | 53.98% | 53.98% | 55.47% | 55.47% | 55.23% | 55.23% | 55.23% | 55.23% | 55.23% | 55.23% | 55.23% | 55.17% | 55.17% | 55.17% | 56.40% | 56.40% | 56.40% | 56.79% | 56.79% | 56.79% | 56.79% | 56.79% | 56.79% | 56.79% | 57.01% | 57.01% | 57.01% | 56.84% | 59.54% | 59.54% | 59.54% | 59.54% | 59.54% | 59.54% |
| Promoter shares pledgedShare of the promoters' own shares | 34.70% | 34.70% | 32.02% | 32.02% | 31.29% | 31.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Shares in issue | 1,05,18,606 | 1,05,18,606 | 1,10,70,000 | 1,10,70,000 | 1,13,76,000 | 1,17,00,000 | 1,17,00,000 | 1,17,00,000 | 1,17,00,000 | 1,17,00,000 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,22,16,600 | 1,26,51,100 | 1,26,51,100 | 1,26,51,100 | 1,26,51,100 | 1,26,51,100 | 1,26,51,100 | 1,26,51,100 | 1,27,14,600 | 1,27,14,600 | 1,27,14,600 | 1,27,14,600 | 1,35,62,815 | 1,35,62,815 | 1,35,62,815 | 1,35,62,815 | 1,35,62,815 | 1,35,62,815 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 20,28,606 | 20,28,606 | 24,47,300 | 54,50,749 | 56,06,749 | 56,06,749 | 74,41,949 | 60,07,949 | 41,60,749 | 41,60,749 | 59,51,089 | 55,76,089 | 11,13,994 | 11,13,994 | 7,12,600 | 4,56,000 | 3,36,000 | 3,36,000 | 2,60,000 | 2,60,000 | 2,60,000 | 2,60,000 | 0 | 56,44,185 | 56,53,685 | 56,53,685 | 1,40,000 | 1,40,000 | 1,40,000 | 1,40,000 | 63,500 | 63,500 | 0 | 57,51,465 | 65,85,042 | 65,85,042 | – | – | – | – |
| Promoters' shares locked in | 15,43,840 | 15,43,840 | 19,45,234 | 35,27,289 | 36,47,289 | 36,47,289 | 53,84,489 | 53,84,489 | 35,48,289 | 35,48,289 | 54,69,489 | 52,69,489 | 8,57,394 | 8,57,394 | 4,56,000 | 4,56,000 | 3,36,000 | 3,36,000 | 2,60,000 | 2,60,000 | 2,60,000 | 2,60,000 | 0 | 52,66,095 | 52,66,095 | 52,66,095 | 1,40,000 | 1,40,000 | 1,40,000 | 1,40,000 | 0 | 0 | 0 | 54,87,095 | 54,87,095 | 54,87,095 | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. Pledged is the share of the promoters' own shares given to lenders as security. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Medicamen Biotech promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is SHIVALIK RASAYAN LIMITED, 40.46%. The filing names 1 more member with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| SHIVALIK RASAYAN LIMITEDIndian companies, trusts and others | 40.46% | 54,87,095 |
No promoter shares are reported as pledged.
Largest public holders of Medicamen Biotech, filing by filing
Per cent, on the same shares as the split above.
| Holder | Dec 2016Filed 17 Jan | Mar 2017Filed 11 Apr | Jun 2017Filed 7 Jul | Sep 2017Filed 13 Oct | Dec 2017Filed 20 Jan | Mar 2018Filed 18 Apr | Jun 2018Filed 10 Jul | Sep 2018Filed 27 Oct | Dec 2018Filed 20 Jan | Mar 2019Filed 16 Apr | Jun 2019Filed 19 Jul | Sep 2019Filed 9 Oct | Dec 2019Filed 10 Jan | Mar 2020Filed 15 May | Jun 2020Filed 17 Jul | Sep 2020Filed 12 Oct | Dec 2020Filed 18 Jan | Mar 2021Filed 7 Apr | Jun 2021Filed 19 Jul | Sep 2021Filed 20 Oct | Dec 2021Filed 17 Jan | Mar 2022Filed 18 Apr | Jun 2022Filed 15 Jul | Sep 2022Filed 20 Oct | Dec 2022Filed 16 Jan | Mar 2023Filed 19 Apr | Jun 2023Filed 20 Jul | Sep 2023Filed 19 Oct | Dec 2023Filed 12 Jan | Mar 2024Filed 17 Apr | Jun 2024Filed 18 Jul | Sep 2024Filed 8 Oct | Dec 2024Filed 21 Jan | Mar 2025Filed 19 Apr | Jun 2025Filed 24 Jul | Sep 2025Filed 17 Oct | Dec 2025Filed 16 Jan | Mar 2026Filed 16 Apr | Jun 2026Filed 16 Jul | Sep 2026Filed 22 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHARMADANICA A/SForeign companies | 12.36% | 12.36% | 11.74% | 11.74% | 11.78% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | 10.97% | – | 10.59% | – | 10.59% | – | 10.59% | 10.59% | 10.54% | 10.54% | 10.54% | 10.54% | 9.88% | 9.88% | 9.88% | 9.88% | 9.88% | 9.88% |
| GINNERUP CAPITAL APSForeign companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.51% | 1.24% | 1.24% | 1.24% | 1.24% | 1.24% | 1.24% | 1.24% | 1.23% | 1.23% | 1.23% | 1.23% | 2.62% | 2.62% | 2.62% | 2.62% | 2.62% | 2.62% |
| INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRSInvestor education fund | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.29% | 1.28% | – | – | 1.26% |
| RAJESH MADANKey managers | 1.27% | 1.27% | 1.21% | 1.21% | 1.35% | 1.32% | 1.32% | 1.32% | 1.32% | 1.32% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.26% | 1.22% | 1.22% | 1.22% | 1.22% | 1.22% | 1.22% | – | 1.21% | 1.21% | 1.21% | 1.21% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% |
| VIJAY AMICHAND SANGHVIResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.02% | 1.11% | 1.11% | 1.12% |
| Veralogix Holdings(Pty) LtdForeign companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4.42% | 4.42% | 4.42% | 4.42% | 4.42% | – |
| Investor Education and Protection Fund (IEPF)Investor education fund | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.26% | 1.26% | – |
| Ritesh Kantilal OswalResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.14% | 1.15% | 1.15% | 1.15% | 1.15% | – |
| Sanjay BansalDirectors and their relatives | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.66% | 1.66% | 1.66% | 1.66% | 1.66% | 1.66% | 1.66% | 1.66% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.60% | 1.50% | – | – | – | – | – |
| Ashish ChughResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.09% | 1.07% | 1.07% | 1.07% | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – |
| Pharmadanic A/sForeign companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 10.59% | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Om Prakash ChughResident individuals, over ₹2 lakh at face value | – | – | 1.32% | 1.32% | 1.28% | 1.25% | 1.25% | 1.25% | 1.25% | 1.25% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.15% | 1.15% | 1.14% | 1.14% | 1.14% | 1.09% | 1.09% | 1.09% | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Kim Ginnerup ApsOther non-institutions | – | – | – | – | – | – | – | – | – | – | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | 2.51% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Niam International Private LimitedOther non-institutions | – | – | – | – | – | – | – | – | 1.50% | 1.50% | 1.43% | 1.44% | 1.45% | 1.45% | 1.41% | 1.15% | 1.06% | 1.00% | 1.00% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Kedar Nath BansalResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | 1.28% | 1.07% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| TransitResident individuals, over ₹2 lakh at face value | – | – | – | – | – | 2.77% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Rajender S DhawanOther non-institutions | 1.60% | 1.60% | 1.52% | 1.52% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Harsh BansalResident individuals, over ₹2 lakh at face value | – | – | 1.36% | 1.36% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| O P ChughResident individuals, over ₹2 lakh at face value | 1.39% | 1.39% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Manju BansalResident individuals, over ₹2 lakh at face value | 1.05% | 1.05% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.